Kura Oncology (KURA) Other Non-Current Liabilities (2022 - 2026)

Kura Oncology has reported Other Non-Current Liabilities over the past 5 years, most recently at $3.4 million for Q1 2026.

  • Quarterly Other Non-Current Liabilities rose 60.68% to $3.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Mar 2026, up 60.68% year-over-year, with the annual reading at $3.2 million for FY2025, 76.32% up from the prior year.
  • Other Non-Current Liabilities was $3.4 million for Q1 2026 at Kura Oncology, up from $3.2 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $3.4 million in Q1 2026 and troughed at $265000.0 in Q4 2022.
  • The 5-year median for Other Non-Current Liabilities is $1.3 million (2024), against an average of $1.6 million.
  • Year-over-year, Other Non-Current Liabilities skyrocketed 170.94% in 2024 and then soared 60.68% in 2026.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $265000.0 in 2022, then soared by 166.04% to $705000.0 in 2023, then soared by 154.61% to $1.8 million in 2024, then skyrocketed by 76.32% to $3.2 million in 2025, then rose by 8.59% to $3.4 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Other Non-Current Liabilities are $3.4 million (Q1 2026), $3.2 million (Q4 2025), and $3.0 million (Q3 2025).